[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100623238":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":61,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":83,"overallStatus":85,"whyStopped":25,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Cook Children's Health Care System","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Ipratropium Bromide, then Placebo","EXPERIMENTAL","Participants will receive Ipratropium Bromide in their first trial and Placebo in the second trial.",[13,14],"Drug: Ipratropium Bromide","Drug: Normal Saline (Placebo)",{"label":16,"type":10,"description":17,"interventionNames":18},"Placebo, then Ipratropium Bromide","Participants will receive Placebo in their first trial and Ipratropium Bromide in the second trial.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Ipratropium Bromide","Nebulized Ipratropium Bromide (500µg\u002F2.5mL); one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Normal Saline (Placebo)","3 mL of nebulized 0.9% normal saline; one-time dose approximately 75 minutes before exercise, inhaled for 5-8 minutes",[9,16],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"John M Robertson, MD","CONTACT","682-303-4200","john.robertson@cookchildrens.org",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Andreas Kreutzer, PhD","682-303-7576","andy.kreutzer@cookchildrens.org",[41],{"facility":42,"status":25,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Cook Children's Pulmonology (Exercise Respiratory Center)","Prosper","Texas","75078","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-96.80111,33.23623,{"lat":52,"lon":51},[55,56,57,59],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},{"name":37,"role":33,"phone":25,"phoneExt":25,"email":39},{"name":32,"role":58,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"name":37,"role":60,"phone":25,"phoneExt":25,"email":25},"SUB_INVESTIGATOR",{"type":62,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100623238","phase-2-effect-of-ipratropium-bromide-on-eilo-100623238",false,"NCT07394036","Effect of Ipratropium Bromide on EILO","The Effect of Ipratropium Bromide on Exercise-Induced Laryngeal Obstruction (EILO) in Pediatric Patients","Inclusion Criteria:\n\n* Patients must be diagnosed with EILO confirmed by Continuous Laryngoscopy During Exercise\n* Patients must be able to complete exercise testing\n* Patients must report dyspnea\n* Patients must have given assent with parental consent, understand all study procedures, and comply with them for the entire length of the study.\n\nExclusion Criteria:\n\n* Patients that do not have EILO.\n* Patients who did not undergo diagnostic CPET with CLE.\n* Patients with hypersensitivity to atropine or its derivatives due to structural similarity with ipratropium bromide.\n* Patients with a history of atrial flutter and\u002For fibrillation\n* Patients taking anticholinergic medications that cannot be paused for 24 hours.\n* Unable to perform exercise tests\n* Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.\n* Inability or unwillingness of patient or parent\u002Flegally authorized representative to give written informed consent.","ALL","8 Years","17 Years",{"count":74,"type":75},50,"ESTIMATED","INTERVENTIONAL",[78],"PHASE2","The investigators propose a study that compares breathlessness and airway obstruction during intense exercise in 34 children and adolescents with Exercise-Induced Laryngeal Obstruction after breathing in ipratropium bromide or placebo. It is hypothesized that breathlessness and airway obstruction will be lower following breathing in ipratropium bromide compared with placebo.",[81,82],"Exercise-Induced Laryngeal Obstruction","Dyspnea During Activity",[81,84,22],"Shortness of Breath during Exercise","NOT_YET_RECRUITING","2026-05-01",{"date":88,"type":89},"2026-05-05","ACTUAL",{"date":91,"type":75},"2026-06-01",{"date":93,"type":75},"2029-12-31",{"name":5,"class":6},1]